These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27920517)

  • 41. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
    Rodrigo GJ; Neffen H
    Chest; 2015 Aug; 148(2):397-407. PubMed ID: 25798635
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
    Dalal AA; Candrilli SD; Davis KL
    Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD.
    Maltais F; Mahler DA; Pepin V; Nadreau E; Crater GD; Morris AN; Emmett AH; Ferro TJ
    Eur Respir J; 2013 Aug; 42(2):539-41. PubMed ID: 23904549
    [No Abstract]   [Full Text] [Related]  

  • 44. Allergic Bronchopulmonary Candidiasis Mimicking COPD.
    Caillaud D; Costes F; Chalmet P; Payen F
    Am J Med; 2019 Nov; 132(11):e797-e798. PubMed ID: 31226246
    [No Abstract]   [Full Text] [Related]  

  • 45. Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease.
    Hoshino M; Ohtawa J
    Respiration; 2013; 86(4):280-7. PubMed ID: 23880883
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tiotropium bromide.
    Gross NJ
    Chest; 2004 Dec; 126(6):1946-53. PubMed ID: 15596697
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
    Singh D; Brooks J; Hagan G; Cahn A; O'Connor BJ
    Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece.
    Maniadakis N; Tzanakis N; Fragoulakis V; Hatzikou M; Siafakas N
    Curr Med Res Opin; 2006 Aug; 22(8):1599-607. PubMed ID: 16870084
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TORCH and UPLIFT: what has been learned from the COPD "mega-trials"?
    Niewoehner DE
    COPD; 2009 Feb; 6(1):1-3. PubMed ID: 19229702
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What is the role of tiotropium in asthma?: a systematic review with meta-analysis.
    Rodrigo GJ; Castro-Rodríguez JA
    Chest; 2015 Feb; 147(2):388-396. PubMed ID: 25322075
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
    Cazzola M; Andò F; Santus P; Ruggeri P; Di Marco F; Sanduzzi A; D'Amato M
    Pulm Pharmacol Ther; 2007; 20(5):556-61. PubMed ID: 16914336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
    Ferguson GT; Karpel J; Bennett N; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
    NPJ Prim Care Respir Med; 2017 Feb; 27(1):7. PubMed ID: 28154373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD.
    Bateman ED; Kornmann O; Ambery C; Norris V
    Pulm Pharmacol Ther; 2013 Oct; 26(5):581-7. PubMed ID: 23538170
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients.
    Vogelmeier C; Fabbri LM; Rabe KF; Beeh KM; Schmidt H; Metzdorf N; Glaab T
    Respir Med; 2013 Jan; 107(1):75-83. PubMed ID: 23102611
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.
    Briggs DD; Covelli H; Lapidus R; Bhattycharya S; Kesten S; Cassino C
    Pulm Pharmacol Ther; 2005; 18(6):397-404. PubMed ID: 16179215
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The use of inhaled anticholinergics in chronic obstructive pulmonary disease: is there cause for concern of cardiovascular safety?
    McIvor RA
    Pol Arch Med Wewn; 2009 Nov; 119(11):697-8. PubMed ID: 19920792
    [No Abstract]   [Full Text] [Related]  

  • 57. Is sustained pharmacologic lung volume reduction now possible in COPD?
    O'Donnell DE
    Chest; 2006 Mar; 129(3):501-3. PubMed ID: 16537841
    [No Abstract]   [Full Text] [Related]  

  • 58. Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization.
    Ainali NM; Xanthopoulou E; Michailidou G; Zamboulis A; Bikiaris DN
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32859128
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tiotropium could provide benefits in the early stage of COPD, but further studies are needed.
    Cazzola M; Rogliani P
    BMJ Evid Based Med; 2018 Oct; 23(5):183-184. PubMed ID: 29950311
    [No Abstract]   [Full Text] [Related]  

  • 60. The anti-inflammatory properties of tiotropium.
    Benfante A; Braido F; Scichilone N
    Lancet Respir Med; 2018 Aug; 6(8):e37. PubMed ID: 29793856
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.